Table of Contents:
  • Contents: Opportunities for immunotherapy
  • Cytotoxic antibodies
  • Monoclonal antibodies
  • CAR T cells: engineered targeting
  • Checkpoint blockade treatment
  • Therapeutic vaccines
  • Tumour specific neoantigens
  • Current immunotherapy development landscape